Theratechnologies Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Lévesque
- Full Time Employees
- 103
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2015 Peel Street Montreal QC Canada H3A 1T8
- IPO Date
- Feb 13, 2009
- CIK
- 0001512717
- Website
- theratech.com
- Similar Companies
- Business
- Theratechnologies Inc. is a commercial-stage biopharmaceutical company focused on the commercialization of innovative therapies addressing unmet medical needs in HIV and oncology. The company develops and markets prescription products including EGRIFTA (tesamorelin), approved to reduce excess abdominal fat in HIV-infected patients with lipodystrophy; EGRIFTA WR (tesamorelin F8), a simplified formulation recently approved by the FDA; Trogarzo (ibalizumab-uiyk), an injectable treatment for multidrug-resistant HIV-1 infections; and advances a research pipeline targeting oncology indications such as triple negative breast cancer and ovarian cancer. Theratechnologies operates primarily in the United States and Canada, with additional presence in Europe, targeting HIV patients and healthcare providers in the specialty pharmaceutical segment. Founded in 1993 and headquartered in Montreal, Quebec, Canada, the company completed its acquisition by CB Biotechnology LLC, an affiliate of Future Pak LLC, on September 25, 2025, for up to $254 million including $3.01 per share in cash and contingent value rights potentially worth $1.19 per share tied to milestones.
Theratechnologies Announces Completion of Acquisition by Future Pak
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
Theratechnologies Inc. (TH:CA) Special Meeting Of Shareholders Of Theratechnologies Call (Transcript)
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
Theratechnologies Reports Financial Results for the Second Quarter 2025
Theratechnologies to Announce Second Quarter 2025 Financial Results
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
Theratechnologies Reports on its Annual Meeting of Shareholders
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer
Theratechnologies Provides Update on Sale Process
Soleus Capital Issues Letter to The Board of Theratechnologies
Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value
Theratechnologies Inc. (THTX) Q1 2025 Earnings Call Transcript
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update